Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:39pm, Friday, 01'st May 2026
SAN FRANCISCO, May 1, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors gran
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Friday, 01'st May 2026
NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar The
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Friday, 01'st May 2026
LOS ANGELES, May 1, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Nektar Therap
NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the cl
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR
08:40pm, Thursday, 30'th Apr 2026
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers.
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 an
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 an
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Thursday, 30'th Apr 2026
New York, New York--(Newsfile Corp. - April 30, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
10:31am, Thursday, 30'th Apr 2026
LOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar�
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT - Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
09:33am, Thursday, 30'th Apr 2026
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) inv
Wall Street Reassessment: Analyst Opinion Evolution on NKTR NEW YORK, April 30, 2026 /PRNewswire/ -- At least seven major Wall Street firms issued reports on December 16, 2025, each flagging the same
New York, New York--(Newsfile Corp. - April 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February
SHAREHOLDER ALERT Securities Class Action Filed Against Nektar Therapeutics (NKTR)
09:28am, Wednesday, 29'th Apr 2026
New York, New York--(Newsfile Corp. - April 29, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a
Executive Accountability: Jonathan Zalevsky Named in Securities Action NEW YORK, April 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors that Jonathan Zalevsky, Chief Research and Deve
